Mizuho Securities Downgrades Amedisys to HoldBy Austin Angelo
According to TipRanks.com, Skolnick is a 4-star analyst with an average return of 3.3% and a 69.4% success rate. Skolnick covers the Healthcare sector, focusing on stocks such as Kindred Healthcare, Community Health, and LifePoint Health.
Amedisys has an analyst consensus of Strong Buy, with a price target consensus of $56.
The company has a one year high of $55.16 and a one year low of $31.16. Currently, Amedisys has an average volume of 265.5K.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AMED in relation to earlier this year. Most recently, in May 2016, Bruce Perkins, a Director at AMED bought 1,000 shares for a total of $50,210.
Amedisys, Inc. provides hospice and home health care services to the chronic, co-morbid and aging American population. The company focuses on delivering patient-centered care, whether that is home-based recovery and rehabilitation after an operation or injury, care focused on empowering them to manage a chronic disease, palliative care for those with a terminal illness, or hospice care at the end of life. It operates its business through following segments: Home Health and Hospice. The Home Health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Amedisys was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.